Safety and Tolerability of MEDI-545 in Patients Who Have Systemic Lupus Erythematosus (SLE)

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

March 31, 2006

Study Completion Date

October 31, 2007

Conditions
Lupus
Interventions
BIOLOGICAL

MEDI-545

0.3 mg/kg IV (n=6) at Study Day 0

BIOLOGICAL

MEDI 545

0.3 mg/kg IV (n=6) at Study Day 0

BIOLOGICAL

MEDI-545

0.3 mg/kg IV (n=6) at Study Day 0

BIOLOGICAL

MEDI-545

0.3 mg/kg IV (n=6) at Study Day 0

BIOLOGICAL

MEDI-545

0.3 mg/kg IV (n=6) at Study Day 0

Trial Locations (21)

10021

Hospital for Special Surgery, New York

10032

Columbia University Medical Center, New York

16635

Altoona Center for Clinical Research, Duncansville

21205

Johns Hopkins University, School of Medicine, Baltimore

33542

Florida Medical Clinic, Clinical Research Division, Zephyrhills

33614

Tampa Florida Medical Research Group, Tampa

33765

Clinical Research of West Florida, Clearwater

34474

Ocala Rheumatology Research Center, Ocala

35207

Pinnacle Research Group, Anniston

53226

Center for Innovative Therapy, UCSD School of Medicine, Milwaukee

Froedtert Hospital, Medical College of Wisconsin, Milwaukee

55805

St. Mary's Duluth Clinic, Duluth

71130

Louisiana State University Health Sciences Center-Shreveport, Shreveport

73104

Oklahoma Medical Research Foundation, Oklahoma City

75390

University of Texas Southwestern Medical Center, Dallas

90048

Wallace Rheumatic Study Center, Los Angeles

97223

Oregon Medical Research Center, Portland

98195

University of Washington Div. of Rhematology, Seattle

03334

Center for Rhematology, Immunology, and Arthritis, Fort Lauderdale

MST 258

Toronto Western Hospital, Toronto

H3G 1A4

Montreal General Hospital, Montreal

Sponsors

Lead Sponsor

All Listed Sponsors
lead

MedImmune LLC

INDUSTRY